These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 24004351)
1. Growing experience with mTOR inhibitors in pediatric solid organ transplantation. Ganschow R; Pape L; Sturm E; Bauer J; Melter M; Gerner P; Höcker B; Ahlenstiel T; Kemper M; Brinkert F; Sachse MM; Tönshoff B Pediatr Transplant; 2013 Nov; 17(7):694-706. PubMed ID: 24004351 [TBL] [Abstract][Full Text] [Related]
2. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients. Nashan B Clin Transplant; 2013; 27 Suppl 25():16-29. PubMed ID: 23909498 [TBL] [Abstract][Full Text] [Related]
3. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization? Gonzalez-Vilchez F; Vazquez de Prada JA; Paniagua MJ; Gomez-Bueno M; Arizon JM; Almenar L; Roig E; Delgado J; Lambert JL; Perez-Villa F; Sanz-Julve ML; Crespo-Leiro M; Segovia J; Lopez-Granados A; Martinez-Dolz L; Mirabet S; Escribano P; Diaz-Molina B; Farrero M; Blasco T Int J Cardiol; 2014 Jan; 171(1):15-23. PubMed ID: 24309084 [TBL] [Abstract][Full Text] [Related]
4. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Shihab F; Christians U; Smith L; Wellen JR; Kaplan B Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504 [TBL] [Abstract][Full Text] [Related]
5. mTOR inhibitors in pediatric kidney transplantation. Pape L; Ahlenstiel T Pediatr Nephrol; 2014 Jul; 29(7):1119-29. PubMed ID: 23740036 [TBL] [Abstract][Full Text] [Related]
6. Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience. Sert M; Celik A; Kural K; Ersan S; Ataca P; Atila K; Cavdar C; Sifil A; Bora S; Gulay H; Camsari T Ren Fail; 2011; 33(8):789-94. PubMed ID: 21787153 [TBL] [Abstract][Full Text] [Related]
7. Clinical evidence on the use of anti-mTOR drugs in renal transplantation. Hernández D; Martínez D; Gutiérrez E; López V; Gutiérrez C; García P; Cobelo C; Cabello M; Burgos D; Sola E; González-Molina M Nefrologia; 2011; 31(1):27-34. PubMed ID: 21270910 [TBL] [Abstract][Full Text] [Related]
9. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation? Zeier M; Van Der Giet M Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495 [TBL] [Abstract][Full Text] [Related]
10. Long-term maintenance therapy with calcineurin inhibitors: an update. Campistol JM Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445 [TBL] [Abstract][Full Text] [Related]
11. Safety of mTOR inhibitors in adult solid organ transplantation. Ventura-Aguiar P; Campistol JM; Diekmann F Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069 [TBL] [Abstract][Full Text] [Related]
12. Everolimus in clinical practice in long-term liver transplantation: an observational study. Casanovas T; Argudo A; Peña-Cala MC Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237 [TBL] [Abstract][Full Text] [Related]
13. Conversion to everolimus in liver transplant patients with renal dysfunction. Pérez T; Segovia R; Castro L; Roblero JP; Estela R Transplant Proc; 2011; 43(6):2307-10. PubMed ID: 21839260 [TBL] [Abstract][Full Text] [Related]